broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K87909389-003-03-4 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 0.242916 | 5.620316 | 0.708259 | 0.7813 | 0.606037 | 0.682184 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000987 |
BRD-K88510285-001-17-8 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 0.282915 | 2.086297 | 0.38906 | 0.812154 | 0.197372 | 0.294417 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000987 |
BRD-K89014967-001-04-3 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 0.844766 | 0.10884 | -0.018192 | 0.933812 | 1.269399 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000987 |
BRD-K92441787-001-04-1 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 0.776067 | -3.596233 | 0.207778 | 0.841545 | 0.585643 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000987 |
BRD-K92723993-001-17-4 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 16.860089 | 0.696143 | -0.006882 | 1 | 10,457,026.694974 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000987 |
BRD-K95142244-001-01-5 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 1.405455 | 2.225458 | 0.267255 | 1 | 0.030583 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000987 |
BRD-K96123349-236-02-8 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 1.332066 | -0.276035 | -0.167452 | 1 | 0.217128 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000987 |
BRD-K98572433-001-02-9 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 0.877122 | -0.646023 | -0.198704 | 0.911263 | 0.893573 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000987 |
BRD-K99113996-001-02-0 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 0.646996 | 0.979389 | 0.086531 | 0.675289 | 0.000699 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000987 |
BRD-K99749624-001-07-0 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 0.820807 | -0.690194 | -0.033323 | 0.892081 | 0.227927 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000987 |
BRD-M97302542-001-04-4 | ACH-000987 | MEWO_SKIN | MTS010 | 1 | 1.06937 | 0.171535 | -0.017323 | 1 | 0.000431 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000987 |
BRD-A25234499-001-19-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.205082 | -5.013237 | 0.10249 | 1 | 0.003647 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000988 |
BRD-A70858459-001-01-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.775578 | 0.076026 | 0.022864 | 0.87396 | 0.002894 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000988 |
BRD-A74914197-001-02-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.289143 | 3.447911 | 0.240007 | 1 | 0.006024 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000988 |
BRD-K02130563-001-11-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.257935 | 1.047754 | 0.923884 | 0.454543 | 0.007468 | 0.014924 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000988 |
BRD-K03390685-001-01-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | -0.220024 | 3.147956 | 0.407871 | 0.962597 | 8.69814 | 7.746673 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000988 |
BRD-K03406345-001-21-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.96845 | -2.182584 | -0.055344 | 0.969921 | 7.873653 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000988 |
BRD-K03449891-001-08-6 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.014272 | 1.659235 | -0.008458 | 0.992494 | 9.413203 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000988 |
BRD-K03765900-001-01-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.583577 | -0.281993 | 0.133447 | 0.795772 | 0.066804 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000988 |
BRD-K05804044-001-18-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.849627 | 0.294902 | 0.052097 | 1 | 597.691037 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000988 |
BRD-K06814349-304-02-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.098438 | 5.05245 | 0.695237 | 0.835441 | 1.701061 | 1.776467 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000988 |
BRD-K08109215-001-06-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.678904 | 0.650305 | 0.256353 | 0.850556 | 0.112593 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000988 |
BRD-K08542803-001-02-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.169021 | 5.900911 | 0.677717 | 0.68486 | 0.252132 | 0.270393 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000988 |
BRD-K08703257-001-13-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.180013 | 0.520943 | 0.000205 | 1 | 0.166034 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000988 |
BRD-K08799216-001-05-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.287199 | 0.313206 | -0.083974 | 0.675963 | 0.155552 | 2.37896 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000988 |
BRD-K09951645-001-11-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.976663 | -0.074386 | -0.093089 | 0.987833 | 0.249571 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000988 |
BRD-K11267252-001-05-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.835165 | -0.66709 | -0.123307 | 0.964487 | 0.003251 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000988 |
BRD-K11630072-001-13-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 36.189649 | 0.672778 | -0.018895 | 1 | 13,770,628,823,514,676 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000988 |
BRD-K12184916-001-19-6 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.069482 | -0.006935 | -0.014367 | 0.365159 | 54,345,208,528,284,830,000,000,000,000,000,000,000,000,000,000 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000988 |
BRD-K12343256-001-14-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.637674 | 0.143806 | -0.040578 | 1 | 0.023439 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000988 |
BRD-K13049116-001-04-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.147379 | -0.013101 | -0.158078 | 1 | 0.126484 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000988 |
BRD-K13390322-001-06-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.154932 | 8.632737 | 0.781881 | 0.834964 | 1.502814 | 1.568788 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000988 |
BRD-K13514097-001-04-6 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.034797 | 0.001607 | -0.155352 | 0.517644 | 0.1471 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000988 |
BRD-K13662825-001-07-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.146608 | 0.77396 | 0.653915 | 0.637082 | 0.041895 | 0.065598 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000988 |
BRD-K14109347-001-03-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.214477 | 0.988888 | 0.332105 | 0.772539 | 0.641586 | 1.130628 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000988 |
BRD-K15179879-001-03-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.224202 | 1.061174 | 0.843544 | 0.442326 | 0.008857 | 0.015517 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000988 |
BRD-K15600710-066-05-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.238041 | 0.04164 | -0.00304 | 1 | 0.000048 | null | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000988 |
BRD-K16730910-001-10-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.748759 | -0.418368 | -0.055014 | 0.871108 | 0.092079 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000988 |
BRD-K17555800-003-02-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.42172 | -0.333463 | 0.396479 | 0.799844 | 0.00789 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000988 |
BRD-K17610631-001-03-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 3.144706 | 0.10303 | -0.006937 | 1 | 1,118,000,323.840485 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000988 |
BRD-K17743125-001-08-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.307851 | 4.442357 | 0.674114 | 0.860521 | 1.414795 | 1.754637 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000988 |
BRD-K17894950-001-14-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.150292 | -1.289639 | 0.125308 | 1 | 0.027344 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000988 |
BRD-K18961567-001-01-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.226668 | 1.854166 | 0.895642 | 0.91368 | 3.658498 | 5.067103 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000988 |
BRD-K19540840-001-09-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.627157 | 0.666387 | 0.219555 | 0.790208 | 0.040376 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000988 |
BRD-K19687926-001-04-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.746154 | -9.754513 | 0.181111 | 0.90931 | 0.019547 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000988 |
BRD-K19796430-001-05-6 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.896056 | 2.919233 | 0.12779 | 0.913603 | 0.00313 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000988 |
BRD-K22064724-001-01-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.132602 | -7.375437 | -0.006026 | 1 | 0.018941 | null | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000988 |
BRD-K22822991-001-02-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.73564 | -0.869842 | 0.254981 | 1 | 0.000808 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000988 |
BRD-K23228615-001-02-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.162977 | 2.588135 | 0.577752 | 0.905533 | 3.42362 | 3.987279 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000988 |
BRD-K23984367-001-07-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.339202 | 0.342418 | -0.019068 | 1 | 1.332111 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000988 |
BRD-K26026438-001-01-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.576404 | 0.963113 | 0.232325 | 0.854572 | 0.372089 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000988 |
BRD-K26657438-001-15-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.658358 | 0.643069 | 0.048688 | 0.88351 | 0.433914 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000988 |
BRD-K28822270-001-03-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.208434 | 0.263568 | 0.397351 | 0.677003 | 0.403604 | 3.123623 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000988 |
BRD-K29905972-001-06-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 3.316009 | 0.806039 | 0.057831 | 1 | 96.48246 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000988 |
BRD-K30577245-001-05-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.262647 | 0.970776 | 0.362337 | 0.691242 | 0.010909 | 0.023502 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000988 |
BRD-K31698212-001-02-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.806373 | 2.041478 | 0.177008 | 0.896515 | 0.055903 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000988 |
BRD-K31928526-001-02-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.660582 | 1.312819 | 0.048655 | 0.817786 | 0.054555 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000988 |
BRD-K33379087-001-07-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.177195 | 2.897445 | 0.591949 | 0.840392 | 1.524328 | 1.772838 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000988 |
BRD-K33610132-001-02-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.726939 | 0.444624 | 0.000381 | 0.877314 | 0.1455 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000988 |
BRD-K33622447-066-01-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.982005 | 0.118428 | 0.00056 | 0.988714 | 0.00086 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000988 |
BRD-K35520305-001-16-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.732953 | -0.71611 | 0.17267 | 0.843768 | 0.188569 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000988 |
BRD-K36627727-001-05-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.306208 | 0.01859 | -0.005109 | 1 | 0.047271 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000988 |
BRD-K36788280-001-01-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.071183 | -0.140876 | -0.061933 | 1 | 4.08399 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000988 |
BRD-K37379014-001-02-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.308929 | 4.935831 | 0.578189 | 0.793451 | 0.00858 | 0.010426 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000988 |
BRD-K38332599-001-01-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.405861 | 1.889167 | 0.43135 | 0.826062 | 0.585063 | 1.416013 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000988 |
BRD-K38527262-300-01-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.990407 | 0.284846 | 0.002951 | 0.995283 | 0.082259 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000988 |
BRD-K38852836-001-02-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 3.036525 | 1.098251 | 0.080823 | 1 | 2.502457 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000988 |
BRD-K41859756-001-06-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.740433 | 0.52425 | 0.148268 | 1 | 0.42021 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000988 |
BRD-K42495768-001-01-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.65079 | 2.284936 | 0.234692 | 1 | 2.686437 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000988 |
BRD-K42805893-001-04-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.004283 | 0.27486 | -0.082759 | 1 | 0.004864 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000988 |
BRD-K42828737-001-03-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.827877 | -0.452067 | 0.076553 | 1 | 0.000278 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000988 |
BRD-K42898655-001-01-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.473573 | 0.745442 | 0.36756 | 0.59088 | 0.000247 | 0.012754 | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000988 |
BRD-K43389675-001-02-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.250808 | 4.374916 | 0.724029 | 0.64769 | 0.104241 | 0.122228 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000988 |
BRD-K44227013-001-06-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.627703 | 0.73525 | 0.001497 | 0.945861 | 4.407057 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000988 |
BRD-K44408410-001-17-6 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.418381 | 25.869365 | 0.489867 | 0.939032 | 3.615767 | 3.878125 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000988 |
BRD-K44827188-001-06-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.80862 | -0.110832 | -0.002092 | 0.883315 | 4.806169 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000988 |
BRD-K46386702-001-02-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.830952 | -3.470556 | 0.179561 | 0.861927 | 1.690407 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000988 |
BRD-K49328571-001-15-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 6.251901 | 1.810946 | -0.141208 | 1 | 134,514.962901 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000988 |
BRD-K49350383-001-14-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.009226 | -0.816129 | -0.473227 | 1 | 0.095917 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000988 |
BRD-K50010139-001-01-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.848469 | 0.252068 | 0.035541 | 0.914258 | 0.02405 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000988 |
BRD-K50168500-001-07-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.267787 | 0.492716 | 0.173611 | 0.835396 | 2.503943 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000988 |
BRD-K51791723-003-01-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | -0.035979 | 0.51638 | 0.177021 | 0.742592 | 1.654458 | 1.446156 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000988 |
BRD-K51967704-001-03-6 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.115628 | -0.012352 | -0.0038 | 1 | 338,585,752,196,894,100,000,000 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000988 |
BRD-K53414658-001-08-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.772744 | 0.186792 | 0.060642 | 0.882432 | 0.052538 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000988 |
BRD-K53972329-001-07-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.17401 | -0.017125 | -0.005976 | 1 | 0.436971 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000988 |
BRD-K54256913-001-08-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.307441 | 1.982495 | 0.705555 | 0.754725 | 0.321797 | 0.520732 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000988 |
BRD-K54955827-001-02-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.855876 | 0.184451 | 0.000699 | 0.916873 | 0.013069 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000988 |
BRD-K54997624-001-06-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.026644 | -0.079097 | -0.041132 | 1 | 0.005734 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000988 |
BRD-K55187425-236-05-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.418703 | 9.780209 | 0.549626 | 0.708429 | 0.076908 | 0.092607 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000988 |
BRD-K56343971-001-14-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.661039 | 0.855889 | 0.165427 | 0.867865 | 0.236663 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000988 |
BRD-K56981171-001-02-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.650774 | -0.021945 | -0.065256 | 0.818012 | 3.689468 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000988 |
BRD-K57080016-001-15-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.741358 | -0.413742 | 0.068441 | 0.869251 | 0.083783 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000988 |
BRD-K57169635-001-04-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.305727 | 0.102643 | 0.234004 | 0.684362 | 0.476891 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000988 |
BRD-K58435339-001-03-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.594785 | -3.946053 | 0.317923 | 0.69536 | 0.899317 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000988 |
BRD-K58550667-001-08-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.185172 | 4.530295 | 0.709354 | 0.652647 | 0.009979 | 0.011052 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000988 |
BRD-K59317601-001-05-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.164801 | 4.139166 | 0.720457 | 0.728697 | 0.427484 | 0.470844 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000988 |
BRD-K59369769-001-22-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.613319 | 0.571227 | 0.128502 | 1 | 25.748007 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000988 |
BRD-K60866521-001-07-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.669231 | -0.733525 | -0.200122 | 1 | 0.000589 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000988 |
BRD-K60997853-001-02-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.277196 | 2.51601 | 0.48729 | 0.89666 | 2.527932 | 3.485705 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000988 |
BRD-K61192372-001-08-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.588038 | -0.588569 | 0.279345 | 0.887857 | 0.005878 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000988 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.